Status:
COMPLETED
A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will determine the maximum tolerated dose and the dose limiting toxicities (Part 1 of study) and the activity (Part 2 of study) of RO5126766 in patients with metastatic or advanced solid tu...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- advanced and/or metastatic cancer not amenable to standard therapy;
- any solid tumor type (Part 1); malignant melanoma, pancreatic cancer or non-small cell lung cancer (Part 2);
- measurable and/or evaluable disease (Part 1), \>=1 measurable lesion (Part 2);
- ECOG performance status 0-1.
Exclusion
- prior chemotherapy, radiotherapy or immunotherapy within 28 days of first receipt of study drug;
- prior corticosteroids as anti-cancer therapy within 14 days of first receipt of study drug;
- known past or present CNS metastases;
- acute or chronic infection.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00773526
Start Date
November 1 2008
End Date
September 1 2011
Last Update
November 2 2016
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Villejuif, France, 94805
2
Barcelona, Barcelona, Spain, 08003
3
Sutton, United Kingdom, SM2 5PT